Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by qwerty22on Jul 14, 2022 10:58am
113 Views
Post# 34824112

RE:RE:RE:RE:RE:Questions

RE:RE:RE:RE:RE:Questions

I think the 53% PR is POC practically and scientifically. It's never 100% but it's hard to ascribe a solid response like that to anything other than the drug. There is some free docetaxel floating around which could account for it. Maybe that could be the cause but Christain did say that patient failed docetaxel treatment recently after 4 cycles. I think what we can see is they are always ultra cautious in their statements.

SPCEO1 wrote: From a practical perspective, we have POC and indications the drug works. from a scientific perspective, neither has yet been achieved. So the scientists are not going to be satisfied until it is, as they should not be. But we can take away from today's news that we will likely get the scientific proof needed before too much longer. 
 

Bucknelly21 wrote: Kinda find some on this board funny, been waiting for poc and an efficacy signal, we get it finally and its not good enough lol 




<< Previous
Bullboard Posts
Next >>